Rezultati pretraživanja
  1. 8. sij

    Hey! Here is episode 05 of my 2'20, and today we're talking about and , with a focus on , , and /STAT inhibitors in . In less than 3 minutes, this is really a challenge. Please comment and let me know if you like it!!!

  2. 29. kol 2019.

    The phase 3 trial has successfully met its primary endpoint, as reported today by the promoter. ➡️ This contrasts with the trial which did not meet its primary endpoint as reported in August 2018.

  3. 30. kol 2019.

    Now is the perfect timing⏳for a little spotlight💡 on 💊 and its recent development data in 🏥 and it's !

  4. , , ... and others that are coming. This is a great time (never thought) for treatment.

  5. 18. pro 2019.

    TULIP 2 Successful phase 3 trial in BICLA response 47.8% in group vs 31.5% in placebo group (P=0.001)

  6. 29. kol 2019.

    This is good news for patients with met primary end point in TULIP2 so another step forward and another step closer to the clinic

  7. 18. pro 2019.

    🚨🚨 BIG PAPER ALERT🚨🚨 What a month for !!! The (positive) results of study are now published in the NEJM Link: Congrats to and all other investigators & patients.

  8. 4. pro 2019.

    Wonderful news for . Can’t wait to read the paper -2020 could be a big year for lupus approvals with this plus

  9. 20. pro 2019.
  10. 13. sij

    You may have seen a Daily Mail article about the breakthrough treatment . We're excited about this potential treatment option, but felt the article was too sensationalist & didn't answer everyone's questions. Learn about this drug at

  11. 5. svi 2017.

    ➖➖➖➖➖ New Drug ➖➖➖➖➖ Anti interferon 1 receptor monoclonal antibody under trial for treatment of...

  12. 11. lis 2018.

    Excellent talk on biologics in by @ the NWL Lupus Forum!Highlighted the challenges of transitioning phase II>III RCT. Altho phase III for was overall -ve, it was +ve in INF-Hi example of immunologically stratified trial in

  13. 29. kol 2019.
  14. Really good results of TULIP 2 Trial in non-renal meeting primary and secondary end-points . Wonderful news for community!!!

  15. 26. stu 2015.

    shows positive results in during Phase II clinical study via

  16. 13. sij

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.